Session » Muscle Biology, Myositis and Myopathies Poster
-
Abstract Number: 2130
Joint Manifestations in Patients Diagnosed with Idiopathic Inflammatory Myopathy: Multicenter Registry on Inflammatory Myositis from the Rheumatology Society in Madrid, Spain
-
Abstract Number: 2131
Longitudinal Cohort Study of Anti-PM/Scl Myositis Patients: Mild Muscle and Lung Involvement with Prominent Perivascular Inflammation
-
Abstract Number: 2132
Angiogenesis and VEGF-Expressing Cells Are Identified Predominantly in the Fascia Rather Than the Muscle in the Early Phase of Dermatomyositis
-
Abstract Number: 2133
Clinical Characteristics of the Patients with Recurrent Myositis in Polymyositis and Dermatomyositis: A Retrospective Study
-
Abstract Number: 2134
Identification of Multiple Cancer Associated Myositis Specific Antibodies in Idiopathic Inflammatory Myopathies: A Large Longitudinal Cohort Study
-
Abstract Number: 2135
ADAM-17 Is Expressed in the Inflammatory Myopathy, and Is Involved with Interstitial Lung Disease
-
Abstract Number: 2136
Association of HLA-DQA1*05 with the Presence of Interstitial Lung Disease Independent of Autoantibody Status in Caucasian Patients with Polymyositis and Dermatomyositis
-
Abstract Number: 2137
Clinical Factors Associated with Long-Term Damage and Calcinosis in an Adult-Age Referral Population of Juvenile Myositis Patients
-
Abstract Number: 2138
Predictive Factors for Achievement of Sustained Remission with Polymyositis/Dermatomyositis: A Retrospective Single Center Cohort Study in Japan
-
Abstract Number: 2139
Analysis of Required Dose of Corticosteroid As Maintenance Therapy and Related Factors in Patients with Polymyositis/Dermatomyositis
-
Abstract Number: 2140
Infections and Medications Associated with Onset of Myositis in Myovision, a National Myositis Patient Registry
-
Abstract Number: 2141
Quantitative Nailfold Video Capillaroscopy Parameters Correlate with Dermatomyositis Activity and Damage
-
Abstract Number: 2142
Autoantibodies Recognizing Cytosolic 5’-Nucleotidase 1A Are Associated with More Severe Disease in Patients with Juvenile Myositis
-
Abstract Number: 2143
Circulating Endothelial Cells and Endothelial Activation Markers As Disease Activity Measures in Idiopathic Inflammatory Myopathies
-
Abstract Number: 2144
Multiple Serum Cytokine and Chemokine Profiling to Identify Combinational Biomarkers Toward Patients of Polymyositis/Dermatomyositis Complicated with Rapidly Progressive Interstitial Lung Disease
-
Abstract Number: 2145
Anti-CXCR3 Antibody Suppresses Inflammation in C Protein-Induced Myositis Model
-
Abstract Number: 2146
CD4+CXCR4+t Cells in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease
-
Abstract Number: 2147
Dysphagia in Inflammatory Myositis: A Study of the Structural and Physiologic Changes Resulting in Disordered Swallowing
-
Abstract Number: 2148
Association of the Paraoxonase 1 Q192R Genetic Polymorphism with Disease Activity in Dermatomyositis
-
Abstract Number: 2149
Statin Use in a Longitudinal Cohort of Patients with Idiopathic Inflammatory Myopathies
-
Abstract Number: 2150
Serum Microrna-1 Can be a Predictive Marker for Disease Activity of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
-
Abstract Number: 2151
The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
-
Abstract Number: 2152
Mycophenolate Mofetil Treatment with or without a Calcineurin Inhibitor in Resistant Inflammatory Myopathy
-
Abstract Number: 2154
Efficacy of an Intensive 24-Week Physiotherapy Programme in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data from a Single-Center Controlled Study
-
Abstract Number: 2155
Myositis As a Complication of Checkpoint Blockade at a Comprehensive Cancer Center
-
Abstract Number: 2156
Comparison of Patients with Dermatomyositis in a Specialty Clinic Versus Clinical Trial with Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist
-
Abstract Number: 2157
Factors Associated with Clinical Remission of Skin Disease in Dermatomyositis
-
Abstract Number: 2158
HLA-DRB1*04:03/*04:06 As the Genetic Susceptibility to Dermatomyositis Positive for Anti-Transcriptional Intermediary Factor 1-γ Antibody in Japanese Population
-
Abstract Number: 2159
Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings
-
Abstract Number: 2161
Comparison of Clinical Characteristics between African American and Caucasian Patients with Polymyositis and Dermatomyositis and Their Response to Conventional Treatment
-
Abstract Number: 2162
Nailfold Videocapillaroscopy in Idiopathic Inflammatory Myopathies
-
Abstract Number: 2163
Clinical Utilization Patterns and Performance of Commercial Myositis Autoantibody Panels in Routine Practice
-
Abstract Number: 2164
Prognostic Factors in Polymyositis/ Dermatomyositis Patients with Anti-Synthetase Antibodies
-
Abstract Number: 2165
Easily Obtainable Myositis Autoantibody Panel Predictive Factors
-
Abstract Number: 2166
Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Efficacy and Predictive Factors for Clinical Response
-
Abstract Number: 2167
Efficacy and Safety of Rituximab in Anti-Synthetase Positive and Negative Patients with Idiopathic Inflammatory Myopathy– a Registry-Based Study
-
Abstract Number: 2168
Dissociation of FVC and Dlco in Patients with Dermatomyositis and Polymyositis
-
Abstract Number: 2169
A Two-Center Experience with Rituximab in Patients with Primary Idiopathic Myositis and Overlap Myositis: A Retrospective Observational Study
-
Abstract Number: 2170
Near Patient Detection of Anti-MDA5 Antibodies Using Photonic Ring Immunoassays
-
Abstract Number: 2171
Functional Measures and Patient Home Self-Assessments in the Idiopathic Inflammatory Myopathies
-
Abstract Number: 2172
Clinical Significance of Serum Levels of Anti-Transcriptional Intermediary Factor 1-γ Antibody in Patients with Dermatomyositis
-
Abstract Number: 2173
Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies
-
Abstract Number: 2174
Investigating Exercise- and Crossfit-Induced Rhabdomyolysis: Data from a Community Healthcare System